PT-141, also known as Bremelanotide, is a synthetic cyclic research peptide derived from the melanocortin peptide family and structurally related to alpha-melanocyte-stimulating hormone (α-MSH). Unlike compounds that primarily act through vascular pathways, PT-141 has been studied for its interactions with melanocortin receptors within the central nervous system.

PT-141 research has explored its activity at several melanocortin receptor subtypes, particularly MC3R and MC4R. Researchers have investigated these receptor pathways to better understand their involvement in neurological signaling, neuroendocrine communication, and physiological responses associated with melanocortin receptor activation.

Another area of PT-141 research involves the broader melanocortin system, a network of peptides and receptors involved in numerous biological signaling processes. Laboratory studies have used PT-141 to examine receptor-mediated responses and the mechanisms through which melanocortin signaling influences central nervous system activity.

PT-141 has a molecular weight of approximately 1,025.2 g/mol and is synthetically produced for controlled research applications. This 10mg formulation is supplied in a nasal research format for laboratory investigation involving melanocortin receptor biology, neuroendocrine signaling, and related biochemical pathways.